Drug repurposing in Raynaud's phenomenon through adverse event signature matching in the World Health Organization pharmacovigilance database.

Putkaradze ZazaMatthieu RoustitCracowski Jean-LucCharles Khouri

Published in: British journal of clinical pharmacology (2020)

Our ADR signature matching approach suggests that alemtuzumab and fumaric acid could be effective treatments of secondary RP. The latter is currently being investigated as a treatment of pulmonary hypertension in systemic sclerosis.

Keyphrases

systemic sclerosis
adverse drug
interstitial lung disease
pulmonary hypertension
electronic health record
emergency department
drug induced
atomic force microscopy
single molecule